Lantheus Holdings, Inc. Q3 2025 Earnings Recap

LNTH Q3 2025 November 7, 2025

Lantheus reported a solid third quarter in 2025, showcasing resilience in its core PSMA PET franchise despite a slight dip in sales, alongside strategic leadership transitions and preparations for the upcoming F-18 PET formulation launch.

Earnings Per Share Beat

$1.27 vs $1.27 est.

+0.0% surprise

Revenue Beat

384014000 vs 367985150 est.

+4.4% surprise

Market Reaction

1-Day -4.88%

5-Day +1.65%

30-Day +9.05%

Key Takeaways

Q3 sales for PYLARIFY reached $240.6 million, reflecting a year-over-year decrease of 7%, but U.S. volumes showed a positive 3.3% increase.
The company announced a leadership transition with Mary Anne Heino stepping in as interim CEO post Brian Markison's retirement, ensuring continuity in strategic execution.
Lantheus is preparing for the expected launch of the new F-18 PSMA PET formulation in 2026, which aims to enhance production efficiency and patient access.
DEFINITY maintained a strong performance with over 6% year-over-year growth, underscoring its market leadership in ultrasound-enhancing agents.
The neurology franchise, especially Neuraceq, is positioned for growth driven by increasing demand in the Alzheimer's disease imaging market.

This summary was generated by AI from the official earnings call transcript and is provided for informational purposes only. It does not constitute financial advice. For the complete transcript and financial data, visit LNTH on AllInvestView.